Furthermore, in the MCA/1956 sarcoma model, both TREM2 deficiency and anti-TREM2 mAb treatment triggered significant changes in the tumor-infiltrating macrophage population, including a decrease in CX3CR1+ MRC1+ immunosuppressive macrophages and an increase in CD83+ CXCL9+ immunostimulatory macrophages, thus enhancing the activation of CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.